[ XXXX replacement therapy and its derivatives in the prevention and treatment of @entity170 ].

@entity1 @entity172 @entity9646 @entity0 @entity174 @entity604 @entity170 @entity173 @entity134 @entity11347 @entity65 @entity441
@entity9646 replacement therapy (HRT) is an established approach for the treatment and the prevention of @entity170 . Many studies with bone mineral density as primary outcome have shown significant efficacy. Observational studies have indicated a significant reduction of @entity173 risk in cohorts of @entity1 who maintained HRT therapy. The @entity1 's Health Initiative is the first prospective randomised controlled study which showed a positive effect of HRT in terms of @entity173 risk. Unfortunately, this study has been interrupted after 5.2 years because of the unsupportable increase of risk of @entity65 and @entity0 . Compliance with HRT, however, is typically poor because of the potential side effects and possible increased risk of @entity0 . Nevertheless, there is now evidence that lower doses of @entity172 in elderly @entity1 may prevent @entity604 while minimizing the side effects seen with higher doses. Combination therapies using low doses @entity172 should probably be reserved for @entity1 who continue to @entity174 on single therapy. Selective @entity172 receptor modulators (SERMs) are very interesting drugs. The goal of these agents is to maximize the beneficial effect of @entity172 on bone and to minimize or antagonize the deleterious effects on the breast and endometrium. @entity441 , approved for the prevention and the treatment of @entity170 , has been shown to reduce the risks of @entity174 in large clinical trials. However, they don't reduce non vertebral @entity174 . @entity11347 is a synthetic @entity134 that increased bone mineral density at lumbar spine and femoral neck. But no trial has been performed with @entity174 as end point.
